Value Insights
Expert perspectives on HTA, market access & evidence generation
CONITEC and IETS are redefining what evidence counts as sufficient. Does your team know?
8 min readHTA StrategyThree HTA agencies. No AI rules. And dossiers are already arriving with AI inside.
9 min readMarket AccessAI in Pharma Market Access: Where It Already Works — and Where It Still Doesn't
14 min readHTA StrategyWhat Is a Global Value Dossier and How AI Is Transforming It
14 min readCONITEC and IETS are redefining what evidence counts as sufficient. Does your team know?
Latin America's two most influential HTA agencies still have no clear rules on artificial intelligence in evidence. What that means for market access teams.
Three HTA agencies. No AI rules. And dossiers are already arriving with AI inside.
CONITEC, IETS, and CENETEC are Latin America's three most influential HTA agencies. None has a public position today on AI in pharmaceutical evidence. Here is what that means for market access teams.
AI in Pharma Market Access: Where It Works, Where It Doesn't, and Why Brazil Is the Most Urgent Case
Why Brazil concentrates the biggest AI opportunity in LATAM market access: CONITEC, RNDS, gene therapy MEA, and the regulatory gap that will close soon.
AI in Pharma Market Access: Where It Already Works — and Where It Still Doesn't
AI fails in drug discovery and clinical trials. In pharma market access it already delivers. Real benchmarks, LATAM HTA context, and what HEOR teams need to know in 2026.
How to Reduce HTA Evidence Preparation for Payers from Months to Days Using AI
Five-step framework to reduce HTA evidence preparation for payers in LATAM from months to days using AI. Documented benchmarks and implementation guide.
What Is a Global Value Dossier and How AI Is Transforming It
Complete guide to the Global Value Dossier: what it is, how it's built, why it takes so long, and how AI is transforming it in LATAM. With documented benchmarks.